PT3898637T - Derivados de rapamicina - Google Patents

Derivados de rapamicina

Info

Publication number
PT3898637T
PT3898637T PT198365462T PT19836546T PT3898637T PT 3898637 T PT3898637 T PT 3898637T PT 198365462 T PT198365462 T PT 198365462T PT 19836546 T PT19836546 T PT 19836546T PT 3898637 T PT3898637 T PT 3898637T
Authority
PT
Portugal
Prior art keywords
rapamycin derivatives
rapamycin
derivatives
Prior art date
Application number
PT198365462T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3898637T publication Critical patent/PT3898637T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT198365462T 2018-12-18 2019-12-17 Derivados de rapamicina PT3898637T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862781242P 2018-12-18 2018-12-18

Publications (1)

Publication Number Publication Date
PT3898637T true PT3898637T (pt) 2025-02-24

Family

ID=69165426

Family Applications (1)

Application Number Title Priority Date Filing Date
PT198365462T PT3898637T (pt) 2018-12-18 2019-12-17 Derivados de rapamicina

Country Status (20)

Country Link
US (1) US12281125B2 (https=)
EP (1) EP3898637B1 (https=)
JP (1) JP7618553B2 (https=)
KR (1) KR20210105397A (https=)
CN (1) CN113260619B (https=)
AU (1) AU2019409366B2 (https=)
BR (1) BR112021011325A2 (https=)
CA (1) CA3122922A1 (https=)
DK (1) DK3898637T3 (https=)
ES (1) ES3014225T3 (https=)
FI (1) FI3898637T3 (https=)
HR (1) HRP20250197T1 (https=)
HU (1) HUE070859T2 (https=)
LT (1) LT3898637T (https=)
MX (1) MX2021007247A (https=)
PL (1) PL3898637T3 (https=)
PT (1) PT3898637T (https=)
RS (1) RS66527B1 (https=)
SI (1) SI3898637T1 (https=)
WO (1) WO2020128861A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
WO2019241789A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
IL285067B2 (en) 2019-01-22 2025-02-01 Aeovian Pharmaceuticals Inc MTORC Modulators and Their Uses
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
EP4688148A1 (en) * 2023-04-07 2026-02-11 Regeneron Pharmaceuticals, Inc. Selective rapamycin analogs and uses thereof
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
WO1996041865A1 (en) * 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
DE69637641D1 (de) 1995-06-07 2008-09-25 Ariad Gene Therapeutics Inc Auf rapamycin basierende regulation biologischer vorgänge
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
CA2257803C (en) 1996-07-12 2008-12-02 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
JP2002508971A (ja) 1998-01-15 2002-03-26 アリアド・ジーン・セラピューティクス・インコーポレーテッド 多量体キメラ蛋白質を使用する生物学的イベントの調節
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
MX368013B (es) 2001-02-19 2019-09-13 Novartis Ag Tratamiento de cáncer.
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
GB0601406D0 (en) 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
US20090023768A1 (en) 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
WO2008022256A2 (en) 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
WO2011133636A1 (en) 2010-04-20 2011-10-27 Cedars-Sinai Medical Center COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND mTOR INHIBITORS
EP2670758B1 (en) 2011-02-04 2022-09-28 Synthon BV Process for making trisubstituted silyloxyethyl triflates
CN103391780B (zh) 2011-02-16 2015-08-19 诺瓦提斯公司 用于治疗神经变性疾病的治疗剂的组合物
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン, エルエルシー Mtor阻害剤を使用する強化された治療レジメン
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
EP3109250A1 (en) 2015-06-23 2016-12-28 Synbias Pharma AG Method for the synthesis of rapamycin derivatives
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2018204416A1 (en) 2017-05-02 2018-11-08 Revolution Medicines, Inc. Rapamycin analogs as mtor inhibitors
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
US20220202787A1 (en) 2019-03-26 2022-06-30 Novartis Ag Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof

Also Published As

Publication number Publication date
PL3898637T3 (pl) 2025-05-19
HUE070859T2 (hu) 2025-07-28
CN113260619A (zh) 2021-08-13
JP7618553B2 (ja) 2025-01-21
KR20210105397A (ko) 2021-08-26
JP2022514254A (ja) 2022-02-10
MX2021007247A (es) 2021-07-15
LT3898637T (lt) 2025-03-10
CA3122922A1 (en) 2020-06-25
CN113260619B (zh) 2026-02-03
SI3898637T1 (sl) 2025-04-30
HRP20250197T1 (hr) 2025-04-11
AU2019409366A1 (en) 2021-06-10
ES3014225T3 (en) 2025-04-21
EP3898637A1 (en) 2021-10-27
US20220064185A1 (en) 2022-03-03
US12281125B2 (en) 2025-04-22
EP3898637B1 (en) 2024-11-20
FI3898637T3 (fi) 2025-02-24
AU2019409366B2 (en) 2022-10-27
WO2020128861A1 (en) 2020-06-25
DK3898637T3 (da) 2025-02-17
RS66527B1 (sr) 2025-03-31
BR112021011325A2 (pt) 2021-11-16

Similar Documents

Publication Publication Date Title
PL3687999T3 (pl) Pochodne rapamycyny
ZA202204675B (en) New methylquinazolinone derivatives
IL271290A (en) Dihydro-pyrrolo-pyridine derivatives
IL271607A (en) New azaquinoline histories
HUE070924T2 (hu) 2-Hidroxicikloalkán-1-karbamoil-származékok
PT3898637T (pt) Derivados de rapamicina
IL290815A (en) History of alpha-d-galactopyranoside
PL4077334T3 (pl) Pochodne furoindazolu
IL283990A (en) Modified oxopyridine derivatives
ZA202106024B (en) Heterocyclic derivatives
IL290964A (en) A 2-aminoquinazolinone derivative
SG11202012594RA (en) Spirochromane derivatives
LT3796975T (lt) Sulfonilaminobenzamido dariniai
PL3770162T3 (pl) Pochodne dihydrochromenu
GB201919210D0 (en) Dihydro-cyclopenta-isoquinoline derivatives
SG11202006837XA (en) Dihydroindolizinone derivative
HUE072226T2 (hu) Trifenilfoszfóniumhoz kötött szalicilamin származékok
ZA202200181B (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
GB201806948D0 (en) Derivatives